# name
Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?

# metadata.dc.description.abstract[].value
The recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors.

# metadata.dc.relation.ispartof[].value
International Journal of General Medicine, 2017, vol. 10, p. 23-26

# metadata.dc.rights[].value
cc-by-nc (c) Ampudia-Blasco, Francisco Javier, 2017

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?